IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.276
NA - Nord America 525
EU - Europa 217
SA - Sud America 31
AF - Africa 14
OC - Oceania 1
Totale 2.064
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 626
US - Stati Uniti d'America 503
VN - Vietnam 280
CN - Cina 258
FR - Francia 147
IT - Italia 28
HK - Hong Kong 24
BR - Brasile 16
DE - Germania 13
IN - India 13
JP - Giappone 11
MX - Messico 11
PH - Filippine 7
TH - Thailandia 7
BD - Bangladesh 6
IQ - Iraq 6
UZ - Uzbekistan 6
CA - Canada 5
GB - Regno Unito 5
PK - Pakistan 5
SE - Svezia 5
TR - Turchia 5
AR - Argentina 4
ID - Indonesia 4
PL - Polonia 4
TW - Taiwan 4
ZA - Sudafrica 4
ES - Italia 3
KR - Corea 3
MA - Marocco 3
AZ - Azerbaigian 2
BE - Belgio 2
BO - Bolivia 2
CO - Colombia 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
EG - Egitto 2
LB - Libano 2
MY - Malesia 2
PY - Paraguay 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BG - Bulgaria 1
BJ - Benin 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CL - Cile 1
DK - Danimarca 1
ET - Etiopia 1
FI - Finlandia 1
HN - Honduras 1
HU - Ungheria 1
IE - Irlanda 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
MR - Mauritania 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 2.064
Salva come PNG Salva come JPEG
Città #
San Jose 293
Singapore 268
Lauterbourg 142
Ho Chi Minh City 92
Ashburn 61
Hanoi 59
Los Angeles 19
Council Bluffs 17
Da Nang 16
Hong Kong 15
Buffalo 11
Haiphong 8
Milan 7
Beijing 6
Tokyo 6
Boardman 5
Frankfurt am Main 5
Hải Dương 5
Can Tho 4
Denver 4
Johannesburg 4
Mexico City 4
New York 4
Orem 4
Querétaro 4
Rome 4
Shanghai 4
Tashkent 4
Bangkok 3
Chennai 3
Dhaka 3
Jakarta 3
Nuremberg 3
Thanh Mỹ Tây 3
Tân Tiến 3
Atlanta 2
Baku 2
Boston 2
Bình Phước 2
Bến Tre 2
Casablanca 2
Dallas 2
Elk Grove Village 2
Faisalabad 2
Huế 2
London 2
Montreal 2
Mumbai 2
Munich 2
Perugia 2
Philadelphia 2
Reggio Calabria 2
Samarkand 2
Shenzhen 2
São Paulo 2
Thanh Hóa 2
Thái Bình 2
Thái Nguyên 2
Toronto 2
Vinh 2
Vĩnh Long 2
Warsaw 2
Ân Thi 2
Abidjan 1
Adana 1
Addis Ababa 1
Agra 1
Akron 1
Amman 1
Araguaína 1
Arlington Heights 1
Astana 1
Asunción 1
Baghdad 1
Barakaldo 1
Barinas 1
Basra 1
Beauchamps 1
Beirut 1
Bekasi 1
Belgrade 1
Bismarck 1
Biyala 1
Biên Hòa 1
Bogotá 1
Bradenton 1
Brive-la-Gaillarde 1
Cabanatuan City 1
Cabo Frio 1
Cardiff 1
Chaguanas 1
Chandigarh 1
Changsha 1
Charleston 1
Cheongju-si 1
Chicago 1
Chon Buri 1
Chongqing 1
Chuí 1
Cochabamba 1
Totale 1.189
Salva come PNG Salva come JPEG
Nome #
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 35
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 34
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 30
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 29
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 26
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 26
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 25
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 24
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 24
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer : the VanGogh study 23
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 23
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 23
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 23
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 22
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 22
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 22
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 21
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 21
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 21
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 21
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 20
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 20
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 20
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 20
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 19
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study 19
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 19
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 19
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 19
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 18
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 18
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 18
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 18
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 18
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 18
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma 18
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 18
Cabozantinib for the treatment of hepatocellular carcinoma 18
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 17
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 17
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 17
Shaping the landscape of immune oncology in hepatocellular carcinoma 17
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 17
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 17
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 17
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 16
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 16
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 16
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 16
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 16
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 16
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression : a Phase II Study 16
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 16
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 15
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 15
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 15
Reply to Y. Pointreau et al 15
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 15
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 15
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 14
COVID-19 and liver cancer clinical trials: not everything is lost 14
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 14
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 14
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 14
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 14
Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! 14
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 14
Biomarkers in Hepatocellular Carcinoma-Letter 14
Which choice of therapy when many are available? - Current systemic therapies for advanced hepatocellular carcinoma 14
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 14
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 14
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 13
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 13
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 13
Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 13
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 13
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 13
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 13
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 13
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 13
Cabozantinib for the treatment of hepatocellular carcinoma 13
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 12
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 12
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 12
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 12
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 12
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 12
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 12
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 12
Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 12
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 12
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 11
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 11
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy 11
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 11
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer : a safe and effective approach 11
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 11
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 11
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 11
Regorafenib for the treatment of unresectable hepatocellular carcinoma 11
Totale 1.686
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.561
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.561
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/20262.227 0 0 0 0 313 363 568 275 482 226 0 0
Totale 2.227